InterWell Health completes $2.4B three-way merger with Fresenius, Cricket Health
InterWell Health has completed its merger with Fresenius Health Partners and Cricket Health in a deal valued at $2.4 billion. The three-way merger was originally announced in March 2022.
The deal brings together three value-based companies providing kidney care services. The combined companies will operate under the InterWell Health brand, and the new company aims to set a standard in kidney care by partnering with a patient's nephrologist and improving care delivery across the care continuum.
The new InterWell Health will leverage its StageSmart machine learning and predictive glomerular filtration rate (GFR) model (known as pGFR) to identify and conduct risk analysis on patients before they reach kidney failure. This model’s 96% accuracy rate will help slow disease progression. InterWell Health will also leverage its patient engagement platform to grow its reach across the country.
"In a value-based world, it is no longer enough just to provide quality care – providers must help patients change behavior, and this requires a fundamental shift in how we engage patients," InterWell Health CEO Robert Sepucha said in a statement. "The new InterWell Health is bringing together cutting-edge data analytics capabilities that identify high-risk patients with the industry's leading patient engagement platform to deliver a rich in-person and virtual experience where they can immerse themselves in information about their disease.
The company currently provides care for 100,000 patients with kidney disease, and by 2025, they expect that figure will grow to 270,000.
Investors Fresenius Medical Care; Valtruis, a WCAS company; Oak HC/FT; Cigna Ventures; and Blue Shield of California are backers in the standalone company.
Editor's Note: A previous version of this article stated InterWell Health provides care for 270,000 patients with kidney disease, and by 2025, that figure will grow by 100,000 individuals. The company currently provides care to 100,000 patients, with the expectation to grow to 270,000 patients by 2025. We regret the error.